A Phase II Trial of 6-Hydroxymethylacylfulvene (MGI-114) in Patients With Advanced Renal Cell Carcinoma
OBJECTIVES: I. Evaluate the efficacy of 6-hydroxymethylacylfulvene (HMAF) in patients with
metastatic renal cell carcinoma. II. Investigate the safety of HMAF given to this patient
population.
OUTLINE: Patients receive 6-hydroxymethylacylfulvene intravenously for 5 minutes every day
for 5 consecutive days. Treatment is repeated every 28 days in the absence of disease
progression or unacceptable toxicity. Patients are followed after every 2 treatment courses.
PROJECTED ACCRUAL: Approximately 12-37 patients will be accrued for this study within 6-19
months.
Interventional
Primary Purpose: Treatment
William Berg, MD
Study Chair
Sanofi
United States: Federal Government
CDR0000066388
NCT00003390
June 1998
August 2004
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |